FourWorld Capital Management LLC lessened its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 18.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,090,851 shares of the biopharmaceutical company’s stock after selling 251,056 shares during the quarter. Arbutus Biopharma comprises approximately 1.8% of FourWorld Capital Management LLC’s investment portfolio, making the […]
FourWorld Capital Management LLC reduced its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,090,851 shares of the biopharmaceutical company’s stock after selling 251,056 shares during the quarter. Arbutus Biopharma […]
Shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $3.25 and last traded at $2.98, with a volume of 6965681 shares traded. The stock had previously closed at $2.52. Analyst Ratings Changes ABUS has been the subject of several research […]
Equities Research Analysts’ updated eps estimates for Thursday, April 4th: Arbutus Biopharma (NASDAQ:ABUS) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $4.00 price target on the stock. Arcellx (NASDAQ:ACLX) had its outperform rating reaffirmed by analysts at Scotiabank. The firm currently has a $82.00 target price on […]
Kades & Cheifetz LLC bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $41,000. A number of […]